The Latin America, Middle East and Africa Smart Insulin Pens Market would witness market growth of 12.2% CAGR during the forecast period (2023-2030). In the year 2026, the LAMEA market's volume is expected to surge to 117.0 thousand units, showcasing a growth of 13.4% (2023-2030).
The demand for minimally invasive or non-invasive surgeries is rising sharply due to documented cases of patient trauma as well as injuries leading to additional complications. In addition, it is well known that invasive surgical procedures raise the risk of infection because the open wound may harbor microbes that worsen the patient's condition. In order to administer insulin without the need for a needle, medical professionals now rely on smart insulin jet injectors. Insulin is known to enter the bloodstream more quickly with jet injectors. When using an insulin jet injector as opposed to a needle, more of the lower skin layer can be covered by insulin. Consequently, the insulin enters the circulation more quickly than it would following a needle injection.
Emerging technologies are anticipated to drive the market during the forecast period. For example, the ability to scan for insulin levels is a feature of the iSenz adaptor for these pens. It offers the ideal injection angles to maximize the effectiveness of diabetes injection sites. Similarly, Easylog is an Internet-connected adaptor for insulin pens. When treating chronic conditions like diabetes, it gives the patient the proper dosage and improves their level of comfort. A sensor to monitor pen temperature and usage is built into the InsulCheck cap for insulin pens.
Diabetes prevalence has increased throughout the Middle East region. The Gulf region has seen a particularly notable and abrupt rise in diabetes rates; Kuwait, Saudi Arabia, and Bahrain are currently among the ten nations with significant prevalence of type 2 diabetes globally. Additionally, Brazil also faces a significant diabetes burden. The prevalence was estimated at around 9-10% of the population. Diabetes is a growing concern in Argentina, with an estimated prevalence of about 9% of the population. Thus, all these factors will aid in expanding the regional market throughout the forecast period.
The Brazil market dominated the LAMEA Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,296 Thousands by 2030. The Argentina market is showcasing a CAGR of 12.8% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.8% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
The demand for minimally invasive or non-invasive surgeries is rising sharply due to documented cases of patient trauma as well as injuries leading to additional complications. In addition, it is well known that invasive surgical procedures raise the risk of infection because the open wound may harbor microbes that worsen the patient's condition. In order to administer insulin without the need for a needle, medical professionals now rely on smart insulin jet injectors. Insulin is known to enter the bloodstream more quickly with jet injectors. When using an insulin jet injector as opposed to a needle, more of the lower skin layer can be covered by insulin. Consequently, the insulin enters the circulation more quickly than it would following a needle injection.
Emerging technologies are anticipated to drive the market during the forecast period. For example, the ability to scan for insulin levels is a feature of the iSenz adaptor for these pens. It offers the ideal injection angles to maximize the effectiveness of diabetes injection sites. Similarly, Easylog is an Internet-connected adaptor for insulin pens. When treating chronic conditions like diabetes, it gives the patient the proper dosage and improves their level of comfort. A sensor to monitor pen temperature and usage is built into the InsulCheck cap for insulin pens.
Diabetes prevalence has increased throughout the Middle East region. The Gulf region has seen a particularly notable and abrupt rise in diabetes rates; Kuwait, Saudi Arabia, and Bahrain are currently among the ten nations with significant prevalence of type 2 diabetes globally. Additionally, Brazil also faces a significant diabetes burden. The prevalence was estimated at around 9-10% of the population. Diabetes is a growing concern in Argentina, with an estimated prevalence of about 9% of the population. Thus, all these factors will aid in expanding the regional market throughout the forecast period.
The Brazil market dominated the LAMEA Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,296 Thousands by 2030. The Argentina market is showcasing a CAGR of 12.8% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.8% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
Scope of the Study
Market Segments Covered in the Report:
By Usability (Volume, Thousand Units, Revenue, USD Million, 2019-30)- Prefilled
- Reusable
- First Generation Pens
- Second Generation Pens
- USB Connected
- Bluetooth-Enabled
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Smart Insulin Pens Market, By Usability
Chapter 6. LAMEA Smart Insulin Pens Market, By Product
Chapter 7. LAMEA Smart Insulin Pens Market, By End User
Chapter 8. LAMEA Smart Insulin Pens Market, By Country
Chapter 9. Company Profiles
Companies Mentioned
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F. Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Methodology
LOADING...
